ES2173165T3 - Metodo para obtener reactivos para diagnosticos, dosificados y terapias basado en la manifestaciones clinicas de una emfermedad. - Google Patents

Metodo para obtener reactivos para diagnosticos, dosificados y terapias basado en la manifestaciones clinicas de una emfermedad.

Info

Publication number
ES2173165T3
ES2173165T3 ES95902582T ES95902582T ES2173165T3 ES 2173165 T3 ES2173165 T3 ES 2173165T3 ES 95902582 T ES95902582 T ES 95902582T ES 95902582 T ES95902582 T ES 95902582T ES 2173165 T3 ES2173165 T3 ES 2173165T3
Authority
ES
Spain
Prior art keywords
antibodies
disease
molecules
diagnostics
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95902582T
Other languages
English (en)
Inventor
Daniel V Santi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2173165T3 publication Critical patent/ES2173165T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
    • C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/82—Hepatitis associated antigens and antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

SE RECUPERAN ANTICUERPOS Y SE AISLAN DEL SERUM DE UN NUMERO "N" DE PACIENTES, CADA UNO DE LOS CUALES HA TENIDO LA MISMA ENFERMEDAD DADA, DE FORMA QUE CADA UNO DE ESTOS PACIENTES TENGA, DENTRO DE UN AMPLIO NUMERO DE ANTICUERPOS DISTINTOS, ALGUNOS ANTICUERPOS ASOCIADOS UNICAMENTE CON LA MISMA ENFERMEDAD DE INTERES. LOS ANTICUERPOS DE UN PRIMER PACIENTE ESTAN FIJADOS A UNA SUPERFICIE DE SOPORTE. PARA LLEVAR A CABO ARCHIVOS DE SEGUIMIENTO INICIALES DE MOLECULAS, TALES COMO PEPTIDOS MOSTRADOS EN LA SUPERFICIE DE LA BACTERIOFAGIA, SE PONEN EN CONTACTO CON LOS ANTICUERPOS FIJADOS DEL PRIMER PACIENTE BAJO CONDICIONES EN LAS QUE SE PRODUZCA LA UNION. LAS MOLECULAS NO FIJADAS (PEPTIDAS) SE ELIMINAN Y LAS MOLECULAS FIJADAS (PEPTIDAS) SOBRE LA BACTERIOFAGIA SON IDENTIFICADAS. SE REALIZA ENTONCES UN SEGUIMIENTO SECUNDARIO EXTRAYENDO Y ETIQUETANDO LOS ANTICUERPOS DE UN SEGUNDO PACIENTE Y UTILIZANDO LOS ANTICUERPOS ETIQUETADOS PARA PROBAR LAS MOLECULAS (AISLADAS) EN EL SEGUIMIENTO INICIAL.
ES95902582T 1993-11-19 1994-11-17 Metodo para obtener reactivos para diagnosticos, dosificados y terapias basado en la manifestaciones clinicas de una emfermedad. Expired - Lifetime ES2173165T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/155,943 US5492807A (en) 1993-11-19 1993-11-19 Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease

Publications (1)

Publication Number Publication Date
ES2173165T3 true ES2173165T3 (es) 2002-10-16

Family

ID=22557410

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95902582T Expired - Lifetime ES2173165T3 (es) 1993-11-19 1994-11-17 Metodo para obtener reactivos para diagnosticos, dosificados y terapias basado en la manifestaciones clinicas de una emfermedad.

Country Status (11)

Country Link
US (2) US5492807A (es)
EP (2) EP1150121A3 (es)
JP (1) JP3135126B2 (es)
AT (1) ATE213836T1 (es)
AU (1) AU674471B2 (es)
CA (1) CA2175374A1 (es)
DE (1) DE69429999T2 (es)
DK (1) DK0729517T3 (es)
ES (1) ES2173165T3 (es)
PT (1) PT729517E (es)
WO (1) WO1995014110A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
US5492807A (en) * 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
ITPN960013A1 (it) * 1996-02-26 1997-08-26 Marcello Piazza Farmaco atto a proteggere l'individuo dal contagio di epatite virale, ecc.
GB9810756D0 (en) 1998-05-19 1998-07-15 Angeletti P Ist Richerche Bio Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
WO2000023140A1 (en) 1998-10-16 2000-04-27 Mission Medical, Inc. Blood processing system
EP2028187A1 (en) 2000-09-08 2009-02-25 Board Of Regents, The University Of Texas System Human and mouse targeting peptides identified by phage display
US20050074747A1 (en) * 2000-09-08 2005-04-07 Wadih Arap Biopanning and rapid analysis of selective interactive ligands (brasil)
US20040170955A1 (en) * 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
US7452964B2 (en) * 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7420030B2 (en) * 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
EP1418932A4 (en) * 2001-07-18 2006-03-15 Univ Texas ANTIANGIOGENIC CONDITION IN MICE AND PEOPLE WITH RETINAL PHOTOREEPEPTOR DEGENERATION
US8507445B2 (en) * 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20040048243A1 (en) * 2001-09-07 2004-03-11 Wadih Arap Methods and compositions for in vitro targeting
US7671010B2 (en) * 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7863004B2 (en) * 2001-12-04 2011-01-04 Wayne State University Neoepitope detection of disease using protein arrays
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
AU2003903317A0 (en) * 2003-06-27 2003-07-10 Proteome Systems Intellectual Property Pty Ltd Method of isolating a protein
GB0422431D0 (en) * 2004-10-08 2004-11-10 Affitech As Method
WO2006060171A2 (en) * 2004-11-16 2006-06-08 Board Of Regents, The University Of Texas System Methods and compositions related to phage-nanoparticle assemblies
WO2007046818A2 (en) * 2004-11-16 2007-04-26 Board Of Regents, The University Of Texas System Compositions and methods related to synchronous selection of homing peptides for multiple tissues by in vivo phage display
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
WO2011090492A1 (en) 2010-01-19 2011-07-28 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
US10768181B2 (en) 2013-12-17 2020-09-08 The Brigham And Women's Hospital, Inc. Detection of an antibody against a pathogen
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
WO2017132550A1 (en) 2016-01-28 2017-08-03 The Brigham And Women's Hospital, Inc. Detection of an antibody against a pathogen
BR112022013624A2 (pt) * 2020-01-17 2022-09-13 Regeneron Pharma Cromatografia de interação hidrofóbica para depuração viral

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3586772T2 (de) * 1984-07-24 1993-03-04 Coselco Mimotopes Pty Ltd Verfahren zur bestimmung von mimotopen.
US4751181A (en) * 1984-12-31 1988-06-14 Duke University Methods and compositions useful in the diagnosis and treatment of autoimmune diseases
WO1986006487A1 (en) * 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Method for determining mimotopes
US5010175A (en) * 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5182366A (en) * 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
US5492807A (en) * 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease

Also Published As

Publication number Publication date
AU674471B2 (en) 1996-12-19
DE69429999T2 (de) 2002-08-29
WO1995014110A1 (en) 1995-05-26
JPH09500731A (ja) 1997-01-21
EP0729517B1 (en) 2002-02-27
DK0729517T3 (da) 2002-04-22
US5670312A (en) 1997-09-23
PT729517E (pt) 2002-08-30
EP0729517A1 (en) 1996-09-04
ATE213836T1 (de) 2002-03-15
JP3135126B2 (ja) 2001-02-13
EP1150121A2 (en) 2001-10-31
EP1150121A3 (en) 2004-01-07
EP0729517A4 (en) 1997-10-15
DE69429999D1 (de) 2002-04-04
AU1180495A (en) 1995-06-06
CA2175374A1 (en) 1995-05-26
US5492807A (en) 1996-02-20

Similar Documents

Publication Publication Date Title
ES2173165T3 (es) Metodo para obtener reactivos para diagnosticos, dosificados y terapias basado en la manifestaciones clinicas de una emfermedad.
ES2152243T3 (es) Inmunoensayo simultaneo en una etapa.
ATE86739T1 (de) Diagnostischer testtraeger und verfahren zu dessen herstellung.
ES2059478T3 (es) Co-expresion en celulas eucarioticas.
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
ATE458053T1 (de) Menschliche toll-like-rezeptorproteine, zugehörige reagenzien und verfahren
CY1109837T1 (el) Διαγνωστικο και θεραπευτικο επιτοπιο
ES2062971T3 (es) Peptidos de la cubierta de htlv iii.
ES2068404T3 (es) Un metodo para aislar el factor viii.
ES2058908T3 (es) Procedimiento para la separacion y purificacion de sialil-transferasas.
ES8703023A1 (es) Un metodo para diagnostico in vitro a fin de detectar la presencia en un paciente de celulas de cancer u otras celulas que produzcan antigenos muninoros.
ES2144399T3 (es) Clonado del adn de virus de anemia de los pollos.
DK1114864T4 (da) Pattedyrcelleoverfladeantigener samt tilhørende reagenser
AR022236A1 (es) Citoquinas mamiferas purificadas; reactivos y metodos relacionados
ES2072251T3 (es) Composiciones y metodos para la sintesis y ensayo de enquefalinasa.
ATE244299T1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
AR022237A1 (es) Citoquinas mamiferas purificadas; reactivos y metodos relacionados
ES2080047T3 (es) Peptidos hiv y metodos para la deteccion de hiv.
RU2005106841A (ru) Эпитопы т-клеток в эритропоэтине
BRPI0406265B8 (pt) método para análise por eletroforese capilar, método para pesquisa e tipagem de proteínas monoclonais, método de preparação de anticorpos modificados sobrecarregados negativamente e kit para detecção e tipagem de proteínas monoclonais
ATE265533T1 (de) Saeugetierchemokine
RU2005108044A (ru) Эпитопы т-клеток в стафилококковом энтеротоксине в
Franklin et al. Albumin Naskapi variant in North American Indians and Eti Turks.
SE9602677D0 (sv) Methods for determining brain antigens
AR023904A1 (es) Anticuerpos para el antigeno de las celulas dendriticas y sus usos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 729517

Country of ref document: ES